Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Emergent BioSolutions Inc. Common Stock (NY:EBS)

4.710 -0.150 (-3.09%)
Streaming Delayed Price Updated: 2:19 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 639,532
Open 4.820
Bid (Size) 4.710 (4)
Ask (Size) 4.730 (3)
Prev. Close 4.860
Today's Range 4.650 - 4.960
52wk Range 1.820 - 15.10
Shares Outstanding 54,300,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Emergent BioSolutions Announces Stock Repurchase Program
From Emergent BioSolutions
Via GlobeNewswire
Expert Outlook: Emergent BioSolutions Through The Eyes Of 5 Analysts
Via Benzinga

Performance

YTD
-54.1%
-54.1%
1 Month
-31.0%
-31.0%
3 Month
-49.1%
-49.1%
6 Month
-43.6%
-43.6%
1 Year
+104.8%
+104.8%

More News

Read More
Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
From Emergent BioSolutions
Via GlobeNewswire
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
From Emergent BioSolutions
Via GlobeNewswire
Where Emergent BioSolutions Stands With Analysts
Via Benzinga
The Analyst Verdict: Emergent BioSolutions In The Eyes Of 4 Experts
Via Benzinga
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
From Emergent BioSolutions
Via GlobeNewswire
Stocks Drop As Trade War Escalates: What's Driving Markets Tuesday?
Via Benzinga
Topics World Trade
Exposures Tariff
Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing
Via Stocktwits
Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Get insights into the top gainers and losers of Monday's after-hours session.
Via Chartmill
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
From Emergent BioSolutions
Via GlobeNewswire
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
Via Benzinga
Earnings Scheduled For March 3, 2025
Via Benzinga
Nvidia, Tesla Lead Tech Stock Rebound: What's Driving Markets Friday?
Via Benzinga
Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
From Emergent BioSolutions
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
From Emergent BioSolutions
Via GlobeNewswire
Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
From Emergent BioSolutions
Via GlobeNewswire
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
From Emergent BioSolutions
Via GlobeNewswire

Frequently Asked Questions

Is Emergent BioSolutions Inc. Common Stock publicly traded?
Yes, Emergent BioSolutions Inc. Common Stock is publicly traded.
What exchange does Emergent BioSolutions Inc. Common Stock trade on?
Emergent BioSolutions Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Emergent BioSolutions Inc. Common Stock?
The ticker symbol for Emergent BioSolutions Inc. Common Stock is EBS on the New York Stock Exchange
What is the current price of Emergent BioSolutions Inc. Common Stock?
The current price of Emergent BioSolutions Inc. Common Stock is 4.710
When was Emergent BioSolutions Inc. Common Stock last traded?
The last trade of Emergent BioSolutions Inc. Common Stock was at 04/01/25 02:19 PM ET
What is the market capitalization of Emergent BioSolutions Inc. Common Stock?
The market capitalization of Emergent BioSolutions Inc. Common Stock is 255.75M
How many shares of Emergent BioSolutions Inc. Common Stock are outstanding?
Emergent BioSolutions Inc. Common Stock has 256M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.